Sodium Chloride Injection Large Volume (IV) for Infusion in PP Bottles USP/Bp

Name: Sodium Chloride Injection Large Volume (IV) for Infusion in PP Bottles USP/Bp
Brand: Beijing DC-Pharma Co., Ltd.
SKU: 1940979482

Beijing, ChinaBeijing DC-Pharma Co., Ltd.

US$0.12-0.30

20,000 Bottle

Product profile

Application

Internal Medicine

Suitable for

Elderly, Children, Adult

State

Liquid

Model NO.

50ml/100m/200ml/250ml/400ml/500ml

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Guoyaozhunzi

Ingredient

Sodium Chloride

Standard 1

USP

Market

Foreign

Standard 2

Transport Package

PP Bottles in Carton

Specification

50ml/100ml/200ml/250ml/400ml/500ml PP Bottle

Trademark

Manufacturer

Origin

P. R. China

HS Code

3004909099

Production Capacity

10 Million Bottles/Year

Company profile

Years of Export ExperienceHigh Repeat Buyers ChoiceImporters and ExportersMulti-language Pioneer

Beijing DC-Pharma Co., Ltd.

Beijing, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2022-03-25Average Response Time: ≤18hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB

AI-Powered supplier vetting

SummaryBeijing DC-Pharma Co., Ltd. is a China-based limited company in the health and medicine sector, identified as both a trading company and manufacturer/factory. It offers pharmaceutical forms including injections, ampoules, tablets, capsules, and powder, and reports self-operated import and export rights with 41%–50% of sales from exports. Its stated services cover supplier selection, evaluation, production arrangement, transportation coordination, and after-sales support. However, the company has only three employees, one R&D engineer, no new products launched in the past year, no inventory, no overseas warehouse, no overseas agents or branches, and no overseas showroom. Complaint handling and corrective/preventive action procedures exist, but no written records were provided. Audit information identifies TUV Rheinland and an audit validity period from March 24, 2025 to March 23, 2026, but the stated evaluation result is not interpretable as a certification or pass conclusion from the provided data.

Supplier typeThe supplier is identified as a trading company in one record and as both a trading company and manufacturer/factory in another. It is a limited company based in Beijing, China, with health and medicine as its commercial trade sector.

After-Sales capabilityThe supplier states that it provides after-sales support and has procedures for handling customer complaints and corrective/preventive actions. The procedures lack written records, so the existence of a formal process is supported but its demonstrated effectiveness is not.

R&D capabilityThe supplier reports one research and development engineer and no new products launched during the past year. These figures indicate limited demonstrated recent innovation activity.

Customization capabilityThe supplier explicitly reports customization from samples, providing evidence of a sample-based customization service. No broader design or engineering capability is documented.